UNSPSC 51171714: Racecadotril

This classification denotes a protease inhibitor and antidiarrheal agent with the molecular formula C21H23NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 76K53XP4TO, chemically known as glycine, n-(2-((acetylthio)methyl)-1-oxo-3-phenylpropyl)-, phenylmethyl ester but generally known as racecadotril, which bears US NIH Compound Identifier 107751. European Medicines Agency schedules Racecadotril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12435MIG.

UNSPSC 51171714 Racecadotril, a Commodity code, shows minimal recent state and local procurement activity aligned with its pharmaceutical scope. The three recent opportunities tagged to this code involve specimen collection and drug testing services, direct-to-manufacturer prescription program market research, and generic multi-source pharmaceutical distribution through a cooperative purchasing vehicle — none of which involve racecadotril specifically. The mismatch between the code's intended scope (a single antidiarrheal active pharmaceutical ingredient) and the actual work being solicited suggests that state and local buyers are either using this code as a catch-all pharmaceutical classification or tagging opportunities to it without precision. The issuing bodies include a county community corrections department, a state health and human services commission, and a multistate cooperative purchasing alliance spanning state and local government facilities across multiple jurisdictions.

Geographic activity is limited to Texas and Minnesota with secondary coverage in Oregon through the cooperative. Collin County Community Supervision and Corrections Department issued an RFP (2026-327, due July 23, 2026) for offender specimen collection and drug testing services with an estimated contract value of $600,000 over two years plus optional renewals, though this opportunity involves immunoassay screening and confirmatory lab work rather than racecadotril procurement. The Texas Health and Human Services Commission posted an RFI (HHS0017013, April 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription programs — a preliminary market intelligence effort with no award value or formal competitive timeline specified. The Minnesota Department of Administration's Office of State Procurement administered an MMCAP RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers effective July 1, 2026, with contract terms of two years for new vendors and extensions through June 30, 2028 for incumbents. Code activity does not indicate active racecadotril-specific demand among state and local buyers at this time.